男性不育症 中国就医指南

Male infertility is a clinical condition defined as the inability of a male partner to achieve pregnancy with a fertile female partner after 12 months or more of regular, unprotected sexual intercourse. It accounts for approximately 40–50% of all infertility cases globally and affects an estimated 7% of all men. Pathophysiologically, male infertility arises from abnormalities in sperm production (spermatogenesis), sperm function, or sperm delivery. Common underlying mechanisms include varicocele-induced testicular hyperthermia and oxidative stress; genetic disorders such as Klinefelter syndrome (47,XXY) or Y-chromosome microdeletions; hormonal imbalances involving FSH, LH, testosterone, or prolactin; obstructive pathologies (e.g., congenital absence of the vas deferens, post-infectious epididymal blockage); and idiopathic causes where no definitive etiology is identified despite comprehensive evaluation. Environmental and lifestyle risk factors significantly contribute—these include tobacco smoking, excessive alcohol intake, recreational drug use (e.g., anabolic steroids, cannabis), obesity, prolonged heat exposure (e.g., saunas, tight underwear), occupational chemical exposures (pesticides, heavy metals), and chronic systemic illnesses like diabetes or untreated hypothyroidism. Psychosocial impact is profound: men with infertility frequently experience diminished self-esteem, marital strain, social isolation, anxiety, and depression—often underreported due to cultural stigma surrounding masculinity and reproductive capacity. Unlike many chronic diseases, male infertility lacks overt physical symptoms in most cases; diagnosis relies on semen analysis (assessing concentration, motility, morphology, and vitality), hormonal profiling, scrotal ultrasound, genetic testing, and occasionally testicular biopsy. Early, evidence-based intervention improves both biological outcomes and quality of life—restoring agency, reducing emotional distress, and supporting informed family-building decisions including assisted reproductive technologies (ART). Comprehensive care requires multidisciplinary collaboration between urologists, endocrinologists, genetic counselors, and reproductive psychologists within specialized reproductive medicine departments.

# 男性不育症治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

• •适用人群：精液参数轻度异常（如弱精、少精）、性激素正常、无梗阻或解剖畸形者
• •药物治疗（3–6个月疗程）：

- 进阶档（HCG联合HMG+抗氧化复合制剂）：¥4,500–¥9,000/疗程

• •理疗与生活方式干预：阴囊低温理疗、中医针灸（每周2次×12周）：¥3,000–¥6,500
• •配套检查费（初诊必查）：精液常规+形态学+DNA碎片率+性激素六项+阴囊超声：¥1,100–¥1,600

二、手术/微创介入方案

• •适用人群：精索静脉曲张（Ⅱ°以上）、输精管梗阻、隐睾术后残留梗阻、睾丸微石症伴生精障碍
• •显微精索静脉结扎术（金标准）：¥12,000–¥18,500（含术前精液培养+睾丸活检评估）
• •输精管吻合术/附睾-输精管吻合术（显微镜下）：¥22,000–¥35,000
• •术前必需检查：精液培养+支原体/衣原体+染色体核型+Y染色体AZF微缺失：¥2,300–¥3,600

三、特殊复杂方案

• •非梗阻性无精子症（NOA）经皮睾丸穿刺取精（TESA）+ICSI助孕：单周期总费用¥38,000–¥52,000（含取精、胚胎培养、冷冻保存）
• •晚期/耐药性氧化应激型不育：线粒体靶向抗氧化治疗（MitoQ联合维生素E衍生物）：¥8,000–¥15,000/6个月

四、方案快速选择指南

• •预算≤¥5,000：首选药物+生活方式干预，同步完成基础检查；
• •预算¥10,000–¥25,000：精索静脉曲张者优先显微手术；梗阻者评估吻合可行性；
• •无精子症/多次ICSI失败：直接启动TESA+ICSI路径，同步行遗传学筛查。